(Q36846894)

16 August 2017

1 reference

title

The use of bisphosphonates in cancer patients (English)

1 reference

16 August 2017

Shenhong Wu

1

1 reference

PubMed ID

17562434

16 August 2017

William L Dahut

series ordinal

2

1 reference

PubMed ID

17562434

16 August 2017

James L Gulley

series ordinal

3

1 reference

16 August 2017

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

46

1 reference

16 August 2017

5

1 reference

16 August 2017

581-591

1 reference

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

16 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Mechanisms of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Osteoporosis due to cancer treatment: pathogenesis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Effects of ovariectomy in beagle dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Bisphosphonates for malignancy-related bone disease: current status, future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Discovery, clinical development, and therapeutic uses of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Bisphosphanates and Oral Cavity Avascular Bone Necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Avascular necrosis of the jaws: risk factors in metastatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

A systematic review of the role of bisphosphonates in metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Home care versus hospital care in patients with multiple myeloma treated with pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Skeletal metastases in colorectal carcinomas: a Saskatchewan profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701233435

10.1080/02841860701233435

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17562434